We use cookies to make this site as useful as possible. By continuing browsing we assume that you agree to accept cookies in accordance with our cookie policy.
To find out more or to change your cookie settings at any time, see our cookie policy. OK

  • About
  • Careers
  • Select Dechra business
    • Dechra Pharmaceuticals PLC
    • Dechra Manufacturing
  • Sign in
  • Select country
    • Danmark
    • Suomi
    • France
    • Deutschland
    • Österreich
    • Nederland
    • Norge
    • Ireland
    • Italia
    • España
    • Portugal
    • Sverige
    • United Kingdom
    • België
    • USA
    • Canada
    • Polska
    • Hrvatska
    • Bosna i Hercegovina
    • Slovenija
    • Australia
    • México
    • Global
    • By clicking a flag you will be leaving this country website to access another site in the Dechra group not applicable to your territory and which may have different legislation
Dechra Veterinary Products
Your materials (0)
  • Products
  • Therapy Areas
  • Academy
  • News
  • Events
  • Support Materials
  • Contact
  • Your materials (0)
  • You are here:
  • Home
  • / About
  • / Facts
  • Back
  • You are here:
  • Facts
  • Overview
  • History
  • Facts
  • The Dechra Values
Approachable
Agile
True
Listen
Vet
  1. Approachable
  2. Agile
  3. True
  4. Listen
  5. Vet

×

The Headlines

In 2017 Dechra delivered 20 years of growth through our strategic growth drivers Portfolio Focus, Pipeline Delivery, Geographic Expansion and Acquisition. 

Our total revenue of £359.3m in 2017 represents a 45.1% growth on the previous year (at Actual Exchange rate) and 28.3% growth (at Constant Exchange Rate). 

24

NUMBER OF COUNTRIES WHERE WE HAVE A PRESENCE

50+

NUMBER OF COUNTRIES WE COVER WORLDWIDE

£407.1m

TOTAL REVENUE IN 2018


What we do best

Our key areas of expertise span endocrinology, dermatology, cardiology, water soluble powder products and injectable antibiotics, anaesthetics and analgesics, equine medicine and diet and nutrition. Our major products include:

  • Vetoryl® Capsules, for the treatment of canine hyperadrenocorticism (Cushing's syndrome)
  • Dermatology brands Canaural®, Isaderm® Gel and Malaseb® Shampoo
  • Felimazole® Tablets, for treating feline hyperthyroidism
  • Added value pharmaceuticals - Cardisure® and Forthyron®, for treating canine congestive heart disease and hypothyroidism respectively
  • Cyclospray® an antibiotic spray for treating claw / hoof problems like Mortallaro’s disease in cattle and superficial wounds
  • Soludox 50% and Octacillin® for treating respiratory and enteric disease in pigs and poultry
  • Equipalazone®, the anti-inflammatory and analgesic for equine musculoskeletal disorders
  • SPECIFIC™, a complete, vet exclusive premium diet range that provides precise nutritional solutions throughout the lives of cats and dogs.
 
 
 
 
 
 
 
 
 
 
 
 

Navigation

  • Overview
  • History
  • Facts
  • The Dechra Values
Website: Co3
  • Terms of Use
  • Privacy Policy
  • Cookie Policy
  • Sitemap
  • Select Dechra business
    • Dechra Pharmaceuticals PLC
    • Dechra Manufacturing

Sign in

Sign in

Help: Forgot password?

 Don't have a Dechra UK Website account?

It is free and only takes a few minutes - Sign up today ensuring you are on your local country site first.

Register here